<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6816401\results\search\tropicalVirus\results.xml">
  <result pre="&amp;amp; Francis pmcid: 6816401 pmid: 311166911621149 doi: 10.1080/21645515.2019.1621149 : Mini-Review" exact="West Nile" post="virus vaccines – current situation and future directions S."/>
  <result pre="altered, transformed, or built upon in any way.khvi-15-10-1621149.pdf Abstract ABSTRACT" exact="West Nile" post="virus (WNV) is a widely spread human pathogenic arthropod-borne"/>
  <result pre="decades, several vaccine candidates for the protection of humans from" exact="WNV" post="have been developed. Some technologies were transferred into clinical"/>
  <result pre="product. This review summarizes the current status of a human" exact="WNV" post="vaccine and discusses reasons for the lack of clinically"/>
  <result pre="and how it can be addressed during vaccine development. KEYWORDS" exact="West Nile" post="virus vaccines flavivirus antibodies table-count: ref-count: page-count: Introduction West"/>
  <result pre="West Nile virus vaccines flavivirus antibodies table-count: ref-count: page-count: Introduction" exact="West Nile" post="virus (WNV) is a single-stranded RNA virus which belongs"/>
  <result pre="includes several important human arthropod-borne pathogens, such as dengue (DENV)," exact="Zika" post="(ZIKV), tick-borne encephalitis (TBEV), Yellow fever (YFV) or Japanese"/>
  <result pre="pathogens, such as dengue (DENV), Zika (ZIKV), tick-borne encephalitis (TBEV)," exact="Yellow fever" post="(YFV) or Japanese encephalitis (JEV) viruses.1 WNV circulates in"/>
  <result pre="encephalitis (TBEV), Yellow fever (YFV) or Japanese encephalitis (JEV) viruses.1" exact="WNV" post="circulates in birds and is transmitted by many different"/>
  <result pre="among the severe cases.3 Since its first description in 1937" exact="WNV" post="has caused several outbreaks in Africa, Asia and South"/>
  <result pre="than 1,500 fatalities have been recorded until today. In addition," exact="WNV" post="led to countless severe infections among horses and caused"/>
  <result pre="among horses and caused the decline of local bird populations.5,6" exact="WNV" post="outbreaks occur in unpredictable magnitude and localization. In Europe,"/>
  <result pre="in unpredictable magnitude and localization. In Europe, a peak in" exact="WNV" post="circulation was experienced in 2018, in total, 1,503 cases"/>
  <result pre="In addition to countries such as Italy and Greece, where" exact="WNV" post="is endemic already for several years, the virus was"/>
  <result pre="increase in endemic areas over the last decades has made" exact="WNV" post="the arthropod-borne human pathogenic flavivirus with the largest distribution"/>
  <result pre="the arthropod-borne human pathogenic flavivirus with the largest distribution worldwide.9" exact="WNV" post="can be divided into five genetic lineages.10 Lineage 1"/>
  <result pre="capacity of this single-stranded RNA virus to mutate its genome.13" exact="WNV" post="vaccine development Since the (re-)emergence of WNV in the"/>
  <result pre="mutate its genome.13 WNV vaccine development Since the (re-)emergence of" exact="WNV" post="in the late 1990, substantial research has been invested"/>
  <result pre="licensed.14,15 For humans, no vaccine is yet available. To develop" exact="WNV" post="vaccines, different technological platforms were employed, including those from"/>
  <result pre="including those from the licensed vaccines for TBEV, JEV and" exact="YFV" post="(attenuated strains and chemically inactivated viruses) in addition to"/>
  <result pre="recombinant proteins, virus-like particles, RNA-replicons, chimeric flaviviruses, viral vectors expressing" exact="WNV" post="genes, DNA- and RNA vaccines. Several recent reviews have"/>
  <result pre="approaches, so they will not be discussed herein further detail.9,16–19" exact="WNV" post="immunization studies used different experimental setups, such as viral"/>
  <result pre="have led to critically important general conclusions: – protection from" exact="WNV" post="can be achieved by a large variety of immunization"/>
  <result pre="of all vaccine candidates described to be successful – E-protein-based" exact="WNV" post="vaccines are protective against genetic lineages 1 and 2"/>
  <result pre="flaviviruses using the yellow fever vaccine strain or an attenuated" exact="DENV" post="as backbones and a recombinant, insect-cell-derived E protein ectodomain.22–2610.1080/21645515.2019.1621149-T0001Table"/>
  <result pre="as backbones and a recombinant, insect-cell-derived E protein ectodomain.22–2610.1080/21645515.2019.1621149-T0001Table 1." exact="WNV" post="vaccine candidates in clinical testing until today. Candidate vaccine"/>
  <result pre="in 50% of individuals after two doses. I 20 Inactivated" exact="WNV" post="Inactivated using formaldehyde Neutralizing antibodies after three doses. I/II"/>
  <result pre="ChimeriVax-WN02 Recombinant yellow fever vaccine strain expressing the prM/E-fragment of" exact="WNV" post="Neutralizing antibodies (&amp;gt;90%) in younger and older age groups"/>
  <result pre="age groups after one dose II 22 rWN/DEN4Δ30 Recombinant attenuated" exact="DENV" post="expressing the prM/E-fragment of WNV Neutralizing antibodies in 89%"/>
  <result pre="II 22 rWN/DEN4Δ30 Recombinant attenuated DENV expressing the prM/E-fragment of" exact="WNV" post="Neutralizing antibodies in 89% of individuals after two doses."/>
  <result pre="antibodies in all individuals after three doses I 24–25 VRC" exact="WNV" post="DNA plasmid expressing the prM/E fragment Neutralizing antibodies (&amp;gt;90%)"/>
  <result pre="evaluated clinically. Firstly, two doses of a hydrogen peroxide inactivated" exact="WNV" post="vaccine led to detectable neutralizing antibodies in approx. 50%"/>
  <result pre="hydrogen peroxide and formaldehyde.20 Secondly, three doses of formaldehyde inactivated" exact="WNV" post="particles induced high titers of neutralizing antibodies.21 None of"/>
  <result pre="particles induced high titers of neutralizing antibodies.21 None of these" exact="WNV" post="vaccine trials reported any adverse events or safety concerns"/>
  <result pre="events or safety concerns which could impede further clinical testing." exact="WNV" post="induced disease is most severe in the elderly; hence,"/>
  <result pre="phase I trial using the DNA vaccine.22,26,29 Current absence of" exact="WNV" post="vaccine candidates in late stages of clinical development In"/>
  <result pre="clinical development In light of these successful developments, a human" exact="WNV" post="vaccine should already be on the market or at"/>
  <result pre="already several years ago.30 Today, there is still no human" exact="WNV" post="vaccine, and there is no candidate even close to"/>
  <result pre="above, it is possible to obtain protective immune responses to" exact="WNV" post="by using a variety of different immunization technologies. Existing"/>
  <result pre="immunization technologies. Existing flavivirus vaccines also use different approaches: the" exact="YFV" post="vaccine consists of an attenuated virus, whereas TBEV and"/>
  <result pre="unlikely to be responsible for the poor outcome of clinical" exact="WNV" post="vaccine development to date. Initial clinical trials have provided"/>
  <result pre="Initial clinical trials have provided good safety profiles for the" exact="WNV" post="candidate vaccines. The existing flavivirus vaccines against YFV and"/>
  <result pre="for the WNV candidate vaccines. The existing flavivirus vaccines against" exact="YFV" post="and TBEV are in use for decades and are"/>
  <result pre="a recently developed and (at least in some countries) licensed" exact="DENV" post="vaccine has caused substantial discussion on vaccine safety. The"/>
  <result pre="vaccine CYD-TDV was designed to protect against all four major" exact="DENV" post="serotypes and consists of the YFV vaccine virus genetically"/>
  <result pre="against all four major DENV serotypes and consists of the" exact="YFV" post="vaccine virus genetically modified to express the DENV prM/E"/>
  <result pre="of the YFV vaccine virus genetically modified to express the" exact="DENV" post="prM/E proteins. Large clinical efficacy trials revealed a small,"/>
  <result pre="but significant, increase in the risk for hospitalization due to" exact="DENV" post="in individuals naïve to the virus. In contrast, those"/>
  <result pre="observations still have to be determined. Achieving vaccine-mediated protection against" exact="DENV" post="is intrinsically challenging due to the need to equally"/>
  <result pre="debatable to what extent similar problems would occur with a" exact="WNV" post="vaccine. Nevertheless, the only WNV candidate vaccine that underwent"/>
  <result pre="problems would occur with a WNV vaccine. Nevertheless, the only" exact="WNV" post="candidate vaccine that underwent a phase II clinical trial"/>
  <result pre="specific time span. Given the detailed epidemiological information available for" exact="WNV" post="outbreaks in the USA since 1999, it might nevertheless"/>
  <result pre="might nevertheless be possible to identify hotspots with relatively high" exact="WNV" post="incidence, which could be suitable areas for efficacy trials,"/>
  <result pre="has been established. A key result from vaccination studies with" exact="WNV" post="is the capability of antibodies to mediate complete protection."/>
  <result pre="highly similar to other flaviviruses, and in the cases of" exact="YFV" post="or JEV, specific titers in neutralizing antibodies serve as"/>
  <result pre="non-human primates.36 However, non-human primates are much less susceptible to" exact="WNV" post="than they are to YFV, which complicates the establishment"/>
  <result pre="Likewise, the fact that most of the people infected with" exact="WNV" post="do not develop clinical symptoms makes the identification of"/>
  <result pre="larger scale trials. Nevertheless, it cannot be excluded that a" exact="WNV" post="vaccine could obtain market approval by using one of"/>
  <result pre="the vaccine leads to clear clinical and also socioeconomic benefits." exact="WNV" post="can induce severe, even fatal disease. It has caused"/>
  <result pre="alone and 181 deaths in Europe during 2018. Consequently, a" exact="WNV" post="vaccine would save lives and would avoid the suffering"/>
  <result pre="unacceptably high. Two published studies have addressed the cost-effectiveness of" exact="WNV" post="vaccination in the USA, one in 2006,38 the other"/>
  <result pre="the other one in 2017.39 Both investigations conclude that a" exact="WNV" post="vaccine is unlikely to save costs. As case numbers"/>
  <result pre="study participants. Many also rely on sophisticated, but expensive, technologies." exact="WNV" post="is constantly expanding its endemic area, and case numbers,"/>
  <result pre="different genetic variations that are associated with severe forms of" exact="WNV" post="disease, which could lead to more targeted vaccination approaches.40"/>
  <result pre="of an infection, as antibodies against one of the four" exact="DENV" post="serotypes can enhance infection with another serotype. The phenomenon"/>
  <result pre="pathogenesis of human dengue infections remains controversial.45 The emergence of" exact="ZIKV" post="in DENV endemic areas has led to investigations to"/>
  <result pre="human dengue infections remains controversial.45 The emergence of ZIKV in" exact="DENV" post="endemic areas has led to investigations to test potential"/>
  <result pre="might be responsible for some of the severe symptoms of" exact="ZIKV" post="infections, for example, fetal neurological malformations. ADE between DENV"/>
  <result pre="of ZIKV infections, for example, fetal neurological malformations. ADE between" exact="DENV" post="and ZIKV could be demonstrated in cell culture experiments"/>
  <result pre="infections, for example, fetal neurological malformations. ADE between DENV and" exact="ZIKV" post="could be demonstrated in cell culture experiments and in"/>
  <result pre="E-protein.46,47 However, recent epidemiological studies on the effect of pre-existing" exact="DENV" post="immunity on ZIKV infection in regions endemic for both"/>
  <result pre="epidemiological studies on the effect of pre-existing DENV immunity on" exact="ZIKV" post="infection in regions endemic for both viruses report correlations"/>
  <result pre="be addressed and excluded during vaccine development. Immunological cross-reactivity between" exact="WNV" post="and other flaviviruses in serological diagnosis is well described.50"/>
  <result pre="of few studies until now, mainly in the context of" exact="ZIKV" post="emergence. Plasma samples from convalescent human WNV- (but not"/>
  <result pre="human WNV- (but not TBEV-) infections were demonstrated to enhance" exact="ZIKV" post="infections both in vitro and in vivo.51,52 On the"/>
  <result pre="hand, no ADE was observed in mice previously infected with" exact="ZIKV" post="and then challenged with WNV. Depending on the ZIKV"/>
  <result pre="with ZIKV and then challenged with WNV. Depending on the" exact="ZIKV" post="strain used, these animals were even better protected against"/>
  <result pre="ZIKV strain used, these animals were even better protected against" exact="WNV" post="than those naïve to ZIKV.53 The complementary animal experiment"/>
  <result pre="naïve to ZIKV.53 The complementary animal experiment (ZIKV challenge after" exact="WNV" post="infection) has not yet been described. In addition, vaccine-induced"/>
  <result pre="studies. For existing flavivirus vaccines, e.g. the licensed TBEV or" exact="YFV" post="vaccines, the availability of large sets of human sera"/>
  <result pre="candidate for ZIKV, consisting of an RNA coding for a" exact="ZIKV" post="virus-like particle, contains four such point mutations and did"/>
  <result pre="for DENV.57 A similar strategy could be used for a" exact="WNV" post="vaccine. Mutant WNV E-proteins have been developed and shown"/>
  <result pre="similar strategy could be used for a WNV vaccine. Mutant" exact="WNV" post="E-proteins have been developed and shown to significantly diminish"/>
  <result pre="less conserved among flaviviruses. Using only the DIII domain of" exact="WNV" post="has been shown to fully protect mice from lethal"/>
  <result pre="data suggest that this antigen does not induce ADE for" exact="DENV" post="and ZIKV.59–61 Alternatively, a vaccine could predominantly induce protective"/>
  <result pre="could predominantly induce protective T-cell responses and thereby avoid ADE." exact="WNV" post="vaccine approaches based on T-cell epitopes have been described,"/>
  <result pre="the combination with neutralizing antibody-inducing antigens still seems necessary.62,63 Conclusions" exact="WNV" post="remains a significant threat to humans in many parts"/>
  <result pre="would be essential to encounter this global threat. Technologies for" exact="WNV" post="vaccines have been developed, they are protective and safe."/>
  <result pre="SejvarJJ, ZakiSR, LanciottiRS, BodeAV, CampbellGLVirology, pathology, and clinical manifestations of" exact="West Nile" post="virus disease. Emerg Infect Dis. 2005;11:1174–79. doi:10.3201/eid1108.050289b.16102303 4.LanciottiRS, EbelGD,"/>
  <result pre="Crabtree MB, et alComplete genome sequences and phylogenetic analysis of" exact="West Nile" post="virus strains isolated from the United States, Europe, and"/>
  <result pre="10.McMullenAR, AlbayrakH, MayFJ, DavisCT, BeasleyDW, BarrettADMolecular evolution of lineage 2" exact="West Nile" post="virus. J Gen Virol. 2013;94:318–25. doi:10.1099/vir.0.046888-0.23136360 11.BakonyiT, FerencziE, ErdélyiK,"/>
  <result pre="Bán E, Nowotny NExplosive spread of a neuroinvasive lineage 2" exact="West Nile" post="virus in Central Europe, 2008/2009. Vet Microbiol. 2013;165:61–70. doi:10.1016/j.vetmic.2013.03.005.23570864"/>
  <result pre="FiguerolaJ, KorakaP, MartinaB, MorenoA, NowotnyN, PardigonN, et alThe challenge of" exact="West Nile" post="virus in Europe: knowledge gaps and research priorities. Euro"/>
  <result pre="LH, Venter MGenetic determinants of virulence in pathogenic lineage 2" exact="West Nile" post="virus strains. Emerg Infect Dis. 2008;14:222–30. doi:10.3201/eid1402.070457.18258114 14.NgT, HathawayD,"/>
  <result pre="2008;14:222–30. doi:10.3201/eid1402.070457.18258114 14.NgT, HathawayD, JenningsN, ChampD, ChiangYW, ChuHJEquine vaccine for" exact="West Nile" post="virus. Dev Biol (Basel). 2003;114:221–27.14677692 15.El GarchH, MinkeJM, RehderJ,"/>
  <result pre="S, Andreoni C, Audonnet JC, Nordgren R, Juillard V. A" exact="West Nile" post="virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing"/>
  <result pre="Immunopathol. 2008;123:230–39. doi:10.1016/j.vetimm.2008.02.002.18372050 16.IyerAV, KousoulasKGA review of vaccine approaches for" exact="West Nile" post="virus. Int J Environ Res Public Health. 2013;10:4200–23. doi:10.3390/ijerph10094200.24025396"/>
  <result pre="Public Health. 2013;10:4200–23. doi:10.3390/ijerph10094200.24025396 17.UlbertS, MagnussonSETechnologies for the development of" exact="West Nile" post="virus vaccines. Future Microbiol. 2014;9(10):1221–32. doi:10.2217/fmb.14.67.25405890 18.AmannaIJ, SlifkaMKCurrent trends"/>
  <result pre="virus vaccines. Future Microbiol. 2014;9(10):1221–32. doi:10.2217/fmb.14.67.25405890 18.AmannaIJ, SlifkaMKCurrent trends in" exact="West Nile" post="virus vaccine development. Expert Rev Vaccines. 2014;13:589–608. doi:10.1586/14760584.2014.906309.24689659 19.ScherwitzlI1,"/>
  <result pre="trial to evaluate the safety and immunogenicity of an inactivated" exact="West Nile" post="virus Vaccine, HydroVax-001, in healthy adults. Vaccine. 2019;S0264–410X:31699–702. 21.BarrettPN,"/>
  <result pre="22.DayanGH, PugachevK, BevilacquaJ, LangJ, MonathTPPreclinical and clinical development of a" exact="YFV" post="17 D-based chimeric vaccine against West Nile virus. Viruses."/>
  <result pre="clinical development of a YFV 17 D-based chimeric vaccine against" exact="West Nile" post="virus. Viruses. 2013;5:3048–70. doi:10.3390/v5123048.24351795 23.DurbinAP, WrightPF, CoxA, KaguciaW, ElwoodD,"/>
  <result pre="S, Wong TImmunogenicity and protective efficacy of a recombinant subunit" exact="West Nile" post="virus vaccine in rhesus monkeys. Clin Vaccine Immunol. 2009;16:1332–37."/>
  <result pre="Clin Vaccine Immunol. 2009;16:1332–37. doi:10.1128/CVI.00119-09.19641099 25.CollerBA, PaiV, Weeks-LevyC, OgataSARecombinant subunit" exact="West Nile" post="virus vaccine for protection of human subjects. Patent application"/>
  <result pre="Enama ME, Nelson S, Nason M, Gu W, et alA" exact="West Nile" post="virus DNA vaccine utilizing a modified promoter induces neutralizing"/>
  <result pre="vaccine elicits humoral and cellular immunity and protects against lethal" exact="West Nile" post="virus infection in aged mice. J Virol. 2013;87:1926–36. doi:10.1128/JVI.02903-12.23221549"/>
  <result pre="WHO/NIH meeting report on approaches to development and licensure of" exact="Zika" post="vaccine candidates. Vaccine. 2019;37:863–68. doi: 10.1016/j.vaccine.2018.12.04030639461 34.GruberMF, FarizoKM, PrattRD,"/>
  <result pre="after intradermal infection with a European lineage 1 strain of" exact="West Nile" post="virus. PLoS One. 2014;9:e112568. doi:10.1371/journal.pone.0112568.25392925 38.ZohrabianA, HayesEB, PetersenLRCost-effectiveness of"/>
  <result pre="Nile virus. PLoS One. 2014;9:e112568. doi:10.1371/journal.pone.0112568.25392925 38.ZohrabianA, HayesEB, PetersenLRCost-effectiveness of" exact="West Nile" post="virus vaccination. Emerg Infect Dis. 2006;12:375–80. doi:10.3201/eid1203.050782.16704772 39.ShankarMB, StaplesJE,"/>
  <result pre="doi:10.3201/eid1203.050782.16704772 39.ShankarMB, StaplesJE, MeltzerMI, FischerMCost effectiveness of a targeted age-based" exact="West Nile" post="virus vaccination program. Vaccine. 2017;35:3143–51. doi:10.1016/j.vaccine.2016.11.078.28456529 40.CahillME, ConleyS, DeWanAT,"/>
  <result pre="ConleyS, DeWanAT, MontgomeryRRIdentification of genetic variants associated with dengue or" exact="West Nile" post="virus disease: a systematic review and meta-analysis. BMC Infect"/>
  <result pre="UlbertS, PalùGLatest developments and challenges in the diagnosis of human" exact="West Nile" post="virus infection. Expert Rev Anti Infect Ther. 2015;13:327–42. doi:10.1586/14787210.2015.1007044.25641365"/>
  <result pre="De OliveraD, HaganJE, et alImpact of preexisting dengue immunity on" exact="Zika" post="virus emergence in a dengue endemic region. Science. 2019;363:607–10."/>
  <result pre="patterns and their consequences for the diagnosis and control of" exact="West Nile" post="disease. Int J Environ Res Public Health. 2013;10:6049–83. doi:10.3390/ijerph10116049.24225644"/>
  <result pre="DuehrJ, FrereJJ, BrownJA, NachbagauerR, FosterGA, KrysztofD, TortorellaD, et alEnhancement of" exact="Zika" post="virus pathogenesis by preexisting antiflavivirus immunity. Science. 2017;356:175–80. doi:10.1126/science.aal4365.28360135"/>
  <result pre="SaizJC, Martín-AcebesMA, Jiménez de OyaNZika virus infection confers protection against" exact="West Nile" post="virus challenge in mice. Emerg Microbes Infect. 2017;6:e81. doi:10.1038/emi.2017.68.28928416"/>
  <result pre="TrainorNB, ChangGJA detailed mutagenesis study of flavivirus cross-reactive epitopes using" exact="West Nile" post="virus-like particles. J Gen Virol. 2007;88:1169–74. doi:10.1099/vir.0.82640-0.17374760 56.RockstrohA, BarzonL,"/>
  <result pre="doi:10.1016/j.cell.2017.02.017.28222903 58.ChabierskiS, BarzonL, PapaA, NiedrigM, BramsonJL, RichnerJM, PalùG, DiamondMS, UlbertSDistinguishing" exact="West Nile" post="virus infection using a recombinant envelope protein with mutations"/>
  <result pre="BürkiK, LiebertUG, UlbertSA DNA vaccine encoding the E protein of" exact="West Nile" post="virus is protective and can be boosted by recombinant"/>
  <result pre="60.MartinaBE, KorakaP, van den DoelP, van AmerongenG, RimmelzwaanGF, OsterhausADImmunization with" exact="West Nile" post="virus envelope domain III protects mice against lethal infection"/>
  <result pre="HeJ, YangM, BaiF, ChenQA plant-produced vaccine protects mice against lethal" exact="West Nile" post="virus infection without enhancing Zika or dengue virus infectivity."/>
  <result pre="protects mice against lethal West Nile virus infection without enhancing" exact="Zika" post="or dengue virus infectivity. Vaccine. 2018;36:1846–52. doi:10.1016/j.vaccine.2018.02.073.29490880 62.KimS, LiL,"/>
  <result pre="an immundominant peptide elicit protective T cell immunity against lethal" exact="West Nile" post="virus infection. J Immunol. 2010;184:4423–30. doi:10.4049/jimmunol.0903955.20212098 63.AnticoliS, ManfrediF, ChiozziniC,"/>
 </snippets>
</snippetsTree>
